Recognition and management of adverse cutaneous reactions in patients on enfortumab vedotin and pembrolizumab in the inpatient setting
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-04-01
|
| Series: | JAAD Case Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2352512625000190 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849769314982297600 |
|---|---|
| author | Emma L. Myers, BA Jessica Liu, BA Sabrina M. Shearer, MD Sarah A. Myers, MD Michelle Schneider, MB, BCh, BAO Christopher Hoimes, DO Melodi Javid Whitley, MD, PhD |
| author_facet | Emma L. Myers, BA Jessica Liu, BA Sabrina M. Shearer, MD Sarah A. Myers, MD Michelle Schneider, MB, BCh, BAO Christopher Hoimes, DO Melodi Javid Whitley, MD, PhD |
| author_sort | Emma L. Myers, BA |
| collection | DOAJ |
| format | Article |
| id | doaj-art-5e4b03815fc64cf7bb48e10b4e9e76f0 |
| institution | DOAJ |
| issn | 2352-5126 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Elsevier |
| record_format | Article |
| series | JAAD Case Reports |
| spelling | doaj-art-5e4b03815fc64cf7bb48e10b4e9e76f02025-08-20T03:03:27ZengElsevierJAAD Case Reports2352-51262025-04-0158859210.1016/j.jdcr.2024.12.037Recognition and management of adverse cutaneous reactions in patients on enfortumab vedotin and pembrolizumab in the inpatient settingEmma L. Myers, BA0Jessica Liu, BA1Sabrina M. Shearer, MD2Sarah A. Myers, MD3Michelle Schneider, MB, BCh, BAO4Christopher Hoimes, DO5Melodi Javid Whitley, MD, PhD6University of North Carolina School of Medicine, Chapel Hill, North CarolinaDuke University School of Medicine, Durham, North CarolinaDepartment of Dermatology, Duke University School of Medicine, Durham, North CarolinaDepartment of Dermatology, Duke University School of Medicine, Durham, North CarolinaDepartment of Pathology, Duke University School of Medicine, Durham, North CarolinaDivision on Medical Oncology and Center for Cancer Immunotherapy, Department of Medicine, Duke University School of Medicine, Durham, North CarolinaDepartment of Dermatology, Duke University School of Medicine, Durham, North Carolina; Correspondence to: Melodi Javid Whitley, MD, PhD, Department of Dermatology, Duke University School of Medicine, Box 3515, 40 Medicine Circle, Durham, NC 27710.http://www.sciencedirect.com/science/article/pii/S2352512625000190enfortumabimmune checkpoint inhibitorimmunotherapyoncodermatologypembrolizumabsevere cutaneous adverse reaction |
| spellingShingle | Emma L. Myers, BA Jessica Liu, BA Sabrina M. Shearer, MD Sarah A. Myers, MD Michelle Schneider, MB, BCh, BAO Christopher Hoimes, DO Melodi Javid Whitley, MD, PhD Recognition and management of adverse cutaneous reactions in patients on enfortumab vedotin and pembrolizumab in the inpatient setting JAAD Case Reports enfortumab immune checkpoint inhibitor immunotherapy oncodermatology pembrolizumab severe cutaneous adverse reaction |
| title | Recognition and management of adverse cutaneous reactions in patients on enfortumab vedotin and pembrolizumab in the inpatient setting |
| title_full | Recognition and management of adverse cutaneous reactions in patients on enfortumab vedotin and pembrolizumab in the inpatient setting |
| title_fullStr | Recognition and management of adverse cutaneous reactions in patients on enfortumab vedotin and pembrolizumab in the inpatient setting |
| title_full_unstemmed | Recognition and management of adverse cutaneous reactions in patients on enfortumab vedotin and pembrolizumab in the inpatient setting |
| title_short | Recognition and management of adverse cutaneous reactions in patients on enfortumab vedotin and pembrolizumab in the inpatient setting |
| title_sort | recognition and management of adverse cutaneous reactions in patients on enfortumab vedotin and pembrolizumab in the inpatient setting |
| topic | enfortumab immune checkpoint inhibitor immunotherapy oncodermatology pembrolizumab severe cutaneous adverse reaction |
| url | http://www.sciencedirect.com/science/article/pii/S2352512625000190 |
| work_keys_str_mv | AT emmalmyersba recognitionandmanagementofadversecutaneousreactionsinpatientsonenfortumabvedotinandpembrolizumabintheinpatientsetting AT jessicaliuba recognitionandmanagementofadversecutaneousreactionsinpatientsonenfortumabvedotinandpembrolizumabintheinpatientsetting AT sabrinamshearermd recognitionandmanagementofadversecutaneousreactionsinpatientsonenfortumabvedotinandpembrolizumabintheinpatientsetting AT sarahamyersmd recognitionandmanagementofadversecutaneousreactionsinpatientsonenfortumabvedotinandpembrolizumabintheinpatientsetting AT michelleschneidermbbchbao recognitionandmanagementofadversecutaneousreactionsinpatientsonenfortumabvedotinandpembrolizumabintheinpatientsetting AT christopherhoimesdo recognitionandmanagementofadversecutaneousreactionsinpatientsonenfortumabvedotinandpembrolizumabintheinpatientsetting AT melodijavidwhitleymdphd recognitionandmanagementofadversecutaneousreactionsinpatientsonenfortumabvedotinandpembrolizumabintheinpatientsetting |